HiSiaddi is an innovative foreign trade service provider driven by both technology commercialization and foreign trade. We have established a "1+2+3+4=1" service system and can supply polypropylene glycol sourced from multiple well-known original manufacturers. As a foreign trader with independent R&D capabilities, HiSiaddi has repeatedly resolved customized polypropylene glycol requirements for clients through technological cooperation with manufacturers and precise market demand insight. Below is a case study of HiSiaddi addressing customized polypropylene glycol demands.
Please contact HiSiaddi customer service for more customized service inquiries.
NORD-MED Biomedical of Denmark is a leading Nordic R&D enterprise specializing in medical polymers. With 28 years of expertise in implant-grade polyurethane dressings and absorbable medical sponge substrates, it supplies wound dressings and minimally invasive interventional consumables to public hospitals across Nordic countries. Its raw materials comply with European Pharmacopoeia (EP), REACH and medical device raw material control standards. The company procures customized narrow-distribution polypropylene glycol from BASF on an original equipment basis, with an annual customized PPG purchase volume of 185 tons, making it a typical high-standard premium purchaser.
Due to maintenance shutdowns of local European production facilities, BASF extending the production lead time of customized grades to 5 months, and a cumulative 35% surge in raw material prices, the client launched a domestic Chinese localization development program. It independently sent samples to 4 mainstream domestic PPG manufacturers for customization trials, yet all trials failed within 3 months. Domestic manufacturers’ mass production lines are designed for standard industrial PPG grades (PPG1000/2000) with fixed catalytic systems and polymerization processes, and refuse to retool production lines for small-batch specialty customization. Facing imminent raw material supply disruption for its new dressing production line, the client entrusted HiSiaddi with full-process services including formula decomposition, process customization, gradient sampling and compliant shipment.
1. Target average molecular weight: 2150±30; molecular weight distribution coefficient ≤1.06 (national standard industrial PPG generally ranges from 1.15 to 1.30). Narrow molecular weight distribution is a core requirement for low precipitation and low hemolysis of medical polyurethane elastomers.
2. Hydroxyl value: 52.0±1.2 mgKOH/g; acid value ≤0.01 mgKOH/g; moisture ≤25 ppm; APHA color ≤10.
3. Individual heavy metal contents (potassium, sodium, iron) ≤3 ppb; no residual catalyst impurities to meet EU medical biocompatibility testing requirements.
4. Residual free propylene oxide monomer ≤1 ppm to eliminate skin sensitization risks from dressing contact.
5. Nitrogen-sealed filling, packaged in 200L food-grade internally coated drums; each batch comes with full sets of EU medical-grade COA and English REACH-SDS documents.
The vast majority of domestic PPG manufacturers adopt continuous mass production with traditional KOH alkali catalysis, featuring fixed process parameters, reactor temperature control and propylene oxide dosing rates dedicated to general commercial grades. Switching to DMC double-metal catalysis for narrow-distribution production requires replacing catalyst feeding systems and revamping closed-loop temperature control, which entails high one-time transformation costs. Manufacturers lack incentives to retool for small orders from individual clients and directly decline customized development requests.
Producing narrow-distribution PPG requires segmented starved dosing of propylene oxide and stepwise temperature-controlled polymerization. While 5kg lab-scale samples can easily meet standards, scaling up to ton-level mass production frequently triggers molecular weight drift and increased by-products. Raw material manufacturers only operate mass production equipment without supporting pilot and lab facilities for gradual scale-up verification, leading to severe performance fluctuations across trial batches.
Standard factory outgoing inspections only cover hydroxyl value, moisture and color, without testing trace metal ions, residual propylene oxide or molecular weight distribution. The full suite of medical-specific tests required by the client demands coordination with third-party laboratories, which domestic manufacturers cannot provide alongside EU-recognized medical test reports.
Manufacturers only provide national standard SDS, lacking EP Pharmacopoeia statements of compliance, SVHC screening reports and REACH registration for medical raw material applications. Even if samples meet physical and chemical standards, shipments cannot clear Danish customs and enter warehouses.
Leveraging domestic polyether industrial chain resources, HiSiaddi shortlisted two manufacturers equipped with flexible DMC double-metal catalytic production lines for specialty PPG: Wanhua Chemical and Shandong Haike Xinyuan. Collaborating with the manufacturers’ R&D departments, we decomposed the client’s technical indicators and formulated targeted processes:
1. Replace traditional potassium hydroxide with eco-friendly DMC catalysts to minimize residual metal ions at the source.
2. Adopt a three-stage stepwise temperature rise process combined with slow starved dosing of propylene oxide, implementing segmented temperature-controlled polymerization. Real-time molecular weight monitoring via online gel permeation chromatography ensures the distribution coefficient remains stably within 1.03–1.05, satisfying the mandatory ≤1.06 threshold.
3. Add a negative-pressure high-temperature devolatilization step post-polymerization to strip residual free propylene oxide via vacuum rectification, maintaining residuals at 0.4–0.8 ppm.
1. 10kg lab-scale trial: Finalize the base process and conduct full medical-grade testing by SGS (heavy metals, monomer residuals, molecular weight distribution). Once qualified, 5 batches of 2kg samples are airfreighted to Denmark for medical polyurethane dressing substrate synthesis, followed by cytotoxicity and hemolysis safety testing, with fine-tuning of polymerization holding time as needed.
2. 500kg pilot continuous batches: Run three parallel pilot reactors, conduct 60-day room-temperature stability storage tests on retained samples to monitor post-storage changes in color and hydroxyl value, and solidify a standardized SOP mass production process.
3. 12-ton trial mass production order: HiSiaddi assigns on-site supervisors to monitor central control data end-to-end, sampling every link from incoming propylene oxide raw materials and catalyst feeding to polymerization, devolatilization and filling.
1. Uniform use of pharmaceutical-grade internally coated anti-rust iron drums, with full nitrogen blanketing during filling and English GHS-compliant labels printed on drum surfaces.
2. Partner with EU REACH agents to complete REACH registration for the PPG grade under medical end-use applications, and compile English SDS complying with EU CLP and EP Pharmacopoeia standards, full SGS medical test reports and supplementary biocompatibility statements.
Coordinate priority production scheduling with manufacturers, arrange chemical special container loading, and align shipping schedules for customs declaration and export to Denmark.
1. The 12-ton trial shipment cleared Danish customs in one go. After synthesizing finished medical dressings, substrate precipitation and hemolysis indicators fully matched original BASF materials, and finished dressing yield rose from 95.2% with imported raw materials to 97.8%.
2. Localized customized procurement costs decreased by 31.5% compared to original BASF supplies, completely resolving the client’s supply shortage and price inflation issues. A formal annual 185-ton quarterly supply framework was signed (50 tons Q1, 52 tons Q2, 48 tons Q3, 35 tons Q4).
3. The client launched a new degradable modified PPG R&D project the following year, entrusting HiSiaddi with full directional customization development, while expanding cooperation for modified PPG used in pharmaceutical ointment carriers.
1. Domestic PPG manufacturers primarily mass-produce standardized general bulk commodities. Narrow-distribution DMC-catalyzed medical-grade specialty PPG is non-core production capacity. Restricted by mass production costs and production schedules, manufacturers struggle to independently deliver non-standard high-end customization for overseas clients.
2. Core Value of HiSiaddi: Integrate upstream flexible production capacity resources, downstream medical formulation application expertise, third-party medical testing services and full EU cross-border compliance resources, bridging technical, compliance and process gaps between manufacturers and high-end overseas medical clients.
3. Procurement of mid-to-high-end raw materials for European and American medical and biomaterial industries requires an integrated system of customized indicators, biosafety and cross-border compliance—an end-to-end service chain no single manufacturer can independently cover, forming the core differentiated competitiveness of specialized foreign trade service providers.
Please contact HiSiaddi customer service for more customized service inquiries.
+86-13120989737 
info@hisiaddi.com 
English
